4,780 Shares in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Bought by Genus Capital Management Inc.

Genus Capital Management Inc. purchased a new stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) in the first quarter, according to the company in its most recent filing with the SEC. The fund purchased 4,780 shares of the pharmaceutical company's stock, valued at approximately $2,317,000.

A number of other hedge funds have also added to or reduced their stakes in VRTX. Norges Bank acquired a new position in Vertex Pharmaceuticals during the 4th quarter valued at about $1,374,948,000. GAMMA Investing LLC boosted its stake in Vertex Pharmaceuticals by 60,572.3% during the 1st quarter. GAMMA Investing LLC now owns 2,425,070 shares of the pharmaceutical company's stock valued at $1,175,722,000 after purchasing an additional 2,421,073 shares during the last quarter. Parnassus Investments LLC acquired a new position in Vertex Pharmaceuticals during the 4th quarter valued at about $731,283,000. Capital World Investors boosted its stake in Vertex Pharmaceuticals by 5.7% during the 4th quarter. Capital World Investors now owns 28,325,695 shares of the pharmaceutical company's stock valued at $11,406,667,000 after purchasing an additional 1,514,993 shares during the last quarter. Finally, Capital Research Global Investors boosted its stake in Vertex Pharmaceuticals by 15.8% during the 4th quarter. Capital Research Global Investors now owns 10,428,951 shares of the pharmaceutical company's stock valued at $4,199,713,000 after purchasing an additional 1,426,746 shares during the last quarter. Institutional investors and hedge funds own 90.96% of the company's stock.

Vertex Pharmaceuticals Stock Performance

VRTX stock traded down $10.68 during midday trading on Friday, hitting $468.85. 892,738 shares of the stock traded hands, compared to its average volume of 1,424,305. The stock's fifty day simple moving average is $448.35 and its 200-day simple moving average is $459.98. Vertex Pharmaceuticals Incorporated has a 1-year low of $377.85 and a 1-year high of $519.88. The firm has a market cap of $120.40 billion, a P/E ratio of -119.60 and a beta of 0.41. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.65 and a quick ratio of 2.29.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last posted its quarterly earnings results on Monday, May 5th. The pharmaceutical company reported $4.06 earnings per share for the quarter, missing analysts' consensus estimates of $4.29 by ($0.23). The business had revenue of $2.77 billion for the quarter, compared to analyst estimates of $2.85 billion. Vertex Pharmaceuticals had a negative return on equity of 3.36% and a negative net margin of 8.91%. The business's revenue was up 2.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $4.76 earnings per share. On average, analysts expect that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on VRTX. Needham & Company LLC restated a "hold" rating on shares of Vertex Pharmaceuticals in a research note on Tuesday, May 6th. Cantor Fitzgerald restated an "overweight" rating and issued a $535.00 target price on shares of Vertex Pharmaceuticals in a research note on Tuesday, May 6th. Leerink Partners restated a "market perform" rating and issued a $503.00 target price (down previously from $550.00) on shares of Vertex Pharmaceuticals in a research note on Tuesday, May 6th. HC Wainwright restated a "buy" rating and issued a $550.00 target price on shares of Vertex Pharmaceuticals in a research note on Monday, June 23rd. Finally, Morgan Stanley cut their target price on Vertex Pharmaceuticals from $464.00 to $460.00 and set an "equal weight" rating on the stock in a research note on Friday, June 20th. Fourteen equities research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $511.62.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.